57
Participants
Start Date
October 14, 2021
Primary Completion Date
January 8, 2024
Study Completion Date
July 15, 2024
MK-6194
Subcutaneous injection
MK-6194-matching placebo
Subcutaneous injection
PRA Magyarorszag Kutatasi es Fejlesztesi Kft. ( Site 0302), Budapest
ARENSIA Exploratory Medicine ( Site 0401), Chisinau
Charite Research Organisation GmbH ( Site 0201), Berlin
Carolina's GI Research, LLC ( Site 0105), Raleigh
IHS. Health, LLC ( Site 0104), Kissimmee
Pinnacle Clinical Research ( Site 0103), San Antonio
Southern Star Research Institute ( Site 0101), San Antonio
Inland Empire Clinical Trials, LLC ( Site 0102), Rialto
ARENSIA Exploratory Medicine Georgia ( Site 0801), Tbilisi
Allmedica Badania Kliniczne Sp z o. o. Sp. K. ( Site 0502), Nowy Targ
WIP Warsaw IBD Point Professor Kierkus ( Site 0501), Warsaw
Arensia Exploratory Medicine GmbH Ukraine ( Site 0701), Kyiv
MAC Clinical Research Prescot ( Site 0604), Prescot
Memory Assessment Clinics Ltd ( Site 0601), Blackpool
MAC Clinical Research ( Site 0602), Barnsley
MAC Clinical Research Centre Leeds ( Site 0603), Leeds
MAC Clinical Research Ltd. ( Site 0605), Manchester
Merck Sharp & Dohme LLC
INDUSTRY